NCT04175665

Real-world Health Outcomes in Canadian Patients Using Semaglutide

Semaglutide in Patients With Type 2 Diabetes: Real-world Analysis in the Canadian LMC Diabetes Registry: The SPARE Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,133 (actual)
• Sponsor: LMC Diabetes & Endocrinology Ltd. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are an injectable, non-insulin therapy for patients with type 2 diabetes (T2D). Semaglutide (Ozempic®) is the newest GLP-1 RA to become available in Canada in 2018, and is administered subcutaneously once-weekly. In clinical trials, semaglutide has been superior to placebo and other antihyperglycemic agents in HbA1c reduction and body weight loss. However, there is little real-world evidence available on the effectiveness of semaglutide in real-world clinical practice. To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study will use the Canadian LMC Diabetes Registry to examine the effects of semaglutide on glycemic control, body weight, and other clinical outcomes in patients with T2D who initiate once-weekly semaglutide as part of usual clinical care in a diabetes specialist practice group in Canada.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Semaglutide	Prescription for semaglutide as part of usual clinical practice

Timeline

• Start date: 2020-01-06
• Primary completion: 2020-02-09
• Completion: 2020-02-09
• First posted: 2019-11-25
• Last updated: 2020-02-21

Locations

1 site across 1 country: Canada